edoc

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder : a double-blind, randomized, placebo-controlled study

Kordon, Andreas and Wahl, Karina and Koch, Nicole and Zurowski, Bartosz and Anlauf, Matthias and Vielhaber, Kirsten and Kahl, Kai G. and Broocks, Andreas and Voderholzer, Ulrich and Hohagen, Fritz. (2008) Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder : a double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology, Vol. 28, H. 5. pp. 550-554.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6428668

Downloads: Statistics Overview

Abstract

Although many patients with obsessive-compulsive disorder (OCD) benefit from treatment with serotonin reuptake inhibitors (SRIs), it is estimated that 40% to 60% of them do not respond. The objective of the present study was to evaluate the efficacy of quetiapine added to baseline treatment with SRIs for the treatment of OCD in severely ill adult subjects.; Forty patients (21 men, 19 women) with primary OCD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria participated in a 12-week, double-blind, placebo-controlled trial. They were randomly assigned to dosages of quetiapine titrated up to 400 mg/d (n = 20) or to placebo (n = 20) in addition to their SRI treatment. During the continuation phase (weeks 6-12), subjects received different dosages between 400 and 600 mg/d depending on clinical response. At entry, all patients were unresponsive to at least 1 course of at least 12 weeks of treatment with SRIs at defined doses. The total Yale-Brown Obsessive-Compulsive Scale score was the primary efficacy parameter.; Intention-to-treat, last-observation-carried-forward analysis demonstrated a mean +/- SD decrease in Yale-Brown Obsessive-Compulsive Scale score of 5.2 +/- 5.4 in the quetiapine group and 3.9 +/- 4.9 in the placebo group. The analysis of treatment effects between the 2 groups showed no significant difference. There were no significant group differences in any of the other self-rating scales or clinician-administered rating scales.; In this study, augmentation of SRI treatment with quetiapine in severe OCD had no additional effect.
Faculties and Departments:07 Faculty of Psychology
UniBasel Contributors:Wahl, Karina
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Lippincott Williams & Wilkins
ISSN:0271-0749
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:02 Oct 2015 10:01
Deposited On:02 Oct 2015 10:01

Repository Staff Only: item control page